• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Build, Fuel, and Drive Your Scientific Competitive Vehicle for the Advancement of New Protein Kinase Inhibitor Drugs in Oncology With the Help of This Brand New Report

Posted on: Thursday, 15 November 2007, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c74231) has announced the addition of The Drug Target Atlas of Protein Kinase Inhibitors in Oncology to their offering.

All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance.

First in place, the author has surveyed protein kinase inhibitors in oncology and identified 110 drug targets, belonging to 210 protein kinase inhibitor drugs. This report, The Drug Target Atlas of Protein Kinase Inhibitors in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology.

In the report, the author reports on 139 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 210 PKI drugs designed for the treatment of more than 50 different cancer indications. The highest degree of distinctiveness among PKIs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified PKI drug targets. No less than 519 protein-protein interactions were recognized among 98 of the 110 included PKI drug targets.

The report by the numbers:

- 300+ pages, with almost a hundred different tables. Includes close to 1,000 active links to related resources on the Internet

- 210 Protein kinase inhibitor drugs, under development by 107 investigators, are included, covering more than 600 developmental projects in cancer

- 110 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other PKI drug targets, linked cancer indications, presence in the Cancer Genome Project etc.

- 139 Unique drug target combinations of PKI drugs

- 519 protein-protein interactions among PKI drug targets

- 20 Major signaling pathways covered

This report serves as a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Chapter Titles:

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

5 Introduction

6 PKI Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Protein Kinase Inhibitors

8 Protein Expression Profiles of PKI Drug Targets in Human

9 Protein Kinase Inhibitors in Major Cell Signaling Pathways

10 Protein-Protein Interactions Between Identified PKI Drug Targets

11 Available Biological Structure Data on PKI Drug Targets

12 Drug Target Profiles of Protein Kinase Inhibitory Drug Targets in Oncology

13 Protein Kinase Inhibitor Drug Target Mix by Cancer Indications

14 Protein Kinase Inhibitor Drugs and Targets by Companies

15 Disclaimer

16 Drug Index

17 Company Index

18 Appendix I: PKI Drug Target Mix

4.1 List of Figures

4.2 List of Tables

Companies Mentioned:

- 4SC

- AB Science

- Abbott

- Adnexus Therapeutics

- Aeterna Zentaris

- Aida Pharmaceuticals

- Alethia Biotherapeutics

- Alfacell

- Ambit Biosciences

- Amgen

- Amphora

- Ariad

- Ark Therapeutics

- ArQule

- Array BioPharma

- Astex Therapeutics

- AstraZeneca

- Avalon

- Bayer

- BioImage

- Biomira

- Biotica Technology

- Boehringer Ingelheim

- Bristol-Myers Squibb

- BTG

- Callisto Pharmaceuticals

- Cancer Research Technology

- Celldex

- Center of Molecular Immunology

- Cephalon

- Chlorogen

- Chroma Therapeutics

- Cyclacel

- Cylene Pharmaceuticals

- Cytokine PharmaSciences

- Dainippon Sumitomo Pharma

- DeveloGen

- Dyax

- Ecopia BioSciences

- Eisai

- Eli Lilly

- EntreMed

- ESBATech

- Exelixis

- Galapagos

- Genentech

- Generex

- Genmab

- GlaxoSmithKline

- GlycoGenesys

- Hemispherx Biopharma

- Hoffmann-La Roche

- Idera Pharmaceuticals

- ImClone Systems

- ImmunoGen

- Insmed

- Johnson & Johnson

- Kalypsys

- Kirin Brewery

- Kyowa Hakko

- Locus Pharmaceuticals

- Medarex

- MedImmune

- Merck & Co

- Merck KGaA

- MethylGene

- Millennium

- Nerviano Medical Sciences

- Neuren

- Nicholas Piramal

- NIH

- Nippon Shinyaku

- Novartis

- Novogen

- Onconova

- OSI Pharmaceuticals

- Peregrine Pharmaceuticals

- Pfizer

- Pharmacyclics

- PharmaGap

- PharmaMar

- Pharmexa

- Pierre Fabre

- PIramed

- Plexxikon

- Reata Pharmaceuticals

- Rexahn

- Rigel

- Sanofi-Aventis

- Semafore Pharmaceuticals

- SGX Pharmaceuticals

- SR Pharma

- Sunesis

- SuperGen

- Surface Logix

- Switch Pharma

- Targa Therapeutics

- Telik

- TopoTarget

- Trion Pharma

- UCB

- VasGene Therapeutics

- Velacor Therapeutics

- Vertex Pharmaceuticals

- ViroMed

- Wyeth

- Zenyaku Kogyo

For more information visit http://www.researchandmarkets.com/reports/c74231

Source: Business Wire

More News in this Category